DC-CTL targeting carbonic anhydrase IX gene combined with iAPA therapy in the treatment of renal cell carcinoma

被引：2

作者：

Ma, Heran ^{[1
,2
]}

Tan, Yi ^{[1
,2
]}

Wen, Dingke ^{[1
]}

Qu, Na ^{[1
]}

Kong, Qunfang ^{[1
]}

Li, Kun ^{[3
]}

Ma, Suxia ^{[4
]}

Zhang, Jianhui ^{[1
]}

机构：

[1] Qilu Cell Therapy Technol Co Ltd, 1109 Gangxing San Rd, Jinan 250000, Shandong, Peoples R China

[2] Shandong Yinfeng Life Sci Res Inst, Jinan, Peoples R China

[3] Shandong First Med Univ, Dept Digest, Affiliated Hosp 1, Jinan, Peoples R China

[4] Heze Municipal Hosp, Heze, Shandong, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2021年 / 17卷 / 11期

关键词：

CA9; iAPA; DC-CTL; RCC; SOCS1; immunotherapy; DENDRITIC CELLS; ANTIGEN-PRESENTATION; NEPHRECTOMY; INHIBITION; GROWTH;

D O I：

10.1080/21645515.2021.1955610

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction To deliver specific antigens in tumor immunotherapy, tumor cell lysates are commonly used to sensitize dendritic cells (DCs). However, the lysates possess low immunogenicity and contain many types of non-tumor-related antigens, which may induce autoimmune diseases. Tumor antigen peptides can provide high specificity but are expensive and their short half-lives limit their clinical application. Methods In this study, we used adenovirus to transfer the carbonic anhydrase IX (CA9) gene into DCs to generate specificity to renal cell carcinoma (RCC) which is the most common space-occupying lesion in humans. Inhibition of antigen presentation attenuators (iAPA) technology was also used to enhance the DC delivery capacity. Finally, DCs were co-cultured with cytotoxic T-lymphocytes (CTLs) and the anti-tumor effects were evaluated. Results The results showed that the CA9-DC-CTLs possessed a high specificity to CA9-positive cells and showed stronger anti-tumor activity than GFP-DC-CTLs both in vitro and in vivo. Discussion These findings may suggest a novel treatment option for RCC.

引用

页码：4363 / 4373

页数：11